Hepatitis C: all 2,356 studies

Page 4 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionCompletedNCT02480712Phase 3Results posted
• Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6CompletedNCT02480166Phase 4Results posted
• Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02476617Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionCompletedNCT02472886Phase 3Results posted
• Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816CompletedNCT02468648Phase 2Results posted
• 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir StudyTerminatedNCT02465203Phase 3Results posted
• Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PROCompletedNCT02461745Phase 4Results posted
• A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)CompletedNCT02461563Phase 1Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-InfectionCompletedNCT02457611Phase 2Results posted
• Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of CirrhosisTerminatedNCT02455167Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedNCT02446717Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT02442284Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in BrazilCompletedNCT02442271Phase 3Results posted
• A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530CompletedNCT02441283Phase 2/3Results posted
• Effects of Persistent Innate Immune Activation on Vaccine EfficacyTerminatedNCT02429583Phase 4Results posted
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 InfectionCompletedNCT02413593Phase 2Results posted
• Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative VolunteersCompletedNCT02404805Not applicableResults posted
• Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal ImpairmentCompletedNCT02402452Phase 1Results posted
• CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeSCompletedNCT02402218Not applicableResults posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected AdultsCompletedNCT02399345Phase 3Results posted
• Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedNCT02397707Phase 1Results posted
• Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)CompletedNCT02392494Phase 1Results posted
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionCompletedNCT02378961Phase 2Results posted
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionCompletedNCT02378935Phase 2Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)CompletedNCT02358044Phase 3Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation SettingCompletedNCT02350569Phase 2Results posted
• Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02349048Phase 2Results posted
• Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUsCompletedNCT02347345Phase 4Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV InfectionCompletedNCT02346721Phase 3Results posted
• Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedNCT02340962Phase 2Results posted
• Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of ColumbiaCompletedNCT02339038Phase 4Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedNCT02332720Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedNCT02332707Phase 2Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 CirrhoticsCompletedNCT02304159Phase 4Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell DiseaseCompletedNCT02301936Phase 2Results posted
• Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment StudyCompletedNCT02300103Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C InfectionTerminatedNCT02292706Results posted
• A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected ParticipantsCompletedNCT02268864Phase 2Results posted
• A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)CompletedNCT02265237Phase 3Results posted
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedNCT02262728Phase 2Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)CompletedNCT02252016Phase 3Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)CompletedNCT02251990Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV InfectionCompletedNCT02251717Phase 2Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-InfectionCompletedNCT02249182Phase 2Results posted
• HCV-HIV Co-infected Patient Cohort in ThailandCompletedNCT02247440Phase 4Results posted
• Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in EgyptCompletedNCT02247401Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedNCT02243293Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 InfectionCompletedNCT02243280Phase 2Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and CirrhosisCompletedNCT02226549Phase 2Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionCompletedNCT02220998Phase 3Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV InfectionCompletedNCT02219685Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and CirrhosisCompletedNCT02219503Phase 3Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02219490Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated CirrhosisCompletedNCT02219477Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) InfectionCompletedNCT02216422Phase 3Results posted
• SMV + SOF With/Without RBV for IFN-II Patients With CHCCompletedNCT02214420Phase 4Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseCompletedNCT02207088Phase 3Results posted
• Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)CompletedNCT02203149Phase 2/3Results posted
• Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionCompletedNCT02202980Phase 2Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV InfectionCompletedNCT02201953Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionCompletedNCT02201940Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B CirrhosisCompletedNCT02201901Phase 3Results posted
• Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedNCT02194998Phase 2Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02185794Phase 1Results posted
• Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected PatientsCompletedNCT02176525Phase 1Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV InfectionCompletedNCT02175758Phase 2Results posted
• A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedNCT02170727Phase 3Results posted
• The SIM-SOF Trial for Hepatitis CCompletedNCT02168361Phase 4Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02167945Phase 3Results posted
• Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsCompletedNCT02159352Phase 1Results posted
• A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCVCompletedNCT02138253Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)CompletedNCT02133131Phase 2Results posted
• Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With CirrhosisCompletedNCT02128542Phase 4Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding DisordersCompletedNCT02120300Phase 2Results posted
• An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C PatientsTerminatedNCT02118597Results posted
• Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis CCompletedNCT02118012Phase 1/2Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)CompletedNCT02115321Phase 2/3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without CirrhosisCompletedNCT02114177Phase 3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and CirrhosisCompletedNCT02114151Phase 3Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)CompletedNCT02105701Phase 3Results posted
• An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)CompletedNCT02105688Phase 3Results posted
• An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)CompletedNCT02105662Phase 3Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)CompletedNCT02105467Phase 3Results posted
• Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)CompletedNCT02105454Phase 2Results posted
• An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected PatientsCompletedNCT02103439Phase 3Results posted
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedNCT02094443Phase 2Results posted
• Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)CompletedNCT02092350Phase 2/3Results posted
• Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)CompletedNCT02076100Phase 1Results posted
• Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV InfectionCompletedNCT02074514Phase 3Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infectionCompletedNCT02073656Phase 3Results posted
• A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) InfectionCompletedNCT02068222Phase 2Results posted
• Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination TherapyCompletedNCT02060058Phase 3Results posted
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVCompletedNCT02032901Phase 3Results posted
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.CompletedNCT02032888Phase 3Results posted

← Hepatitis C overview